MedTrace Logo

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

NCT01093612 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-11-14

Study results available
· View outcomes & findings →

Summary

RATIONALE: Diagnostic procedures, such as copper Cu 64-DOTA-trastuzumab-labeled PET, may help doctors to plan a better treatment

PURPOSE: This pilot trial is studying copper Cu 64-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab-labeled positron emission tomography (PET) in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Conditions

Interventions

PROCEDURE

positron emission tomography

PET images performed on a GE Discovery 16 Ste PET-CT scanner

RADIATION

copper Cu 64-DOTA-trastuzumab

15 mCi of Cu 64-DOTA-trastuzumab, total trastuzumab dose less than 5 mg.

PROCEDURE

Biopsy

Correlative Studies

OTHER

Immunohistochemistry staining method

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

GENETIC

mutation analysis

Correlative studies

Sponsors & Collaborators

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Joanne Mortimer · City of Hope Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-16
Primary Completion
2018-10-23
Completion
2026-09-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01093612 on ClinicalTrials.gov